October 31, 2018
Ferring Pharmaceuticals today announced that Michel Pettigrew, President of the Executive Board and Chief Operating Officer, will retire from his operational activities effective December 31, 2018. Per Falk, Chief Science Officer, will assume additional responsibility as President of the Executive Committee, effective January 1, 2019.
Michel has had an exceptional career at Ferring, taking the company from revenues of €345 million when he joined the company in 2001 to nearly €2 billion today. In addition, Ferring is now in the Top 50 Global Pharma Companies 2018.
“I would like to express my sincere appreciation for Michel’s commitment to Ferring, his considerable achievements and his passion for supporting patients and helping people live better lives,” said Frederik Paulsen, Chairman of the Ferring Board of Directors. “I wish Per every success in his expanded leadership role. With his strong scientific and medical background, Per will lead Ferring with the Executive Committee to its next phase of growth and innovation.”
Per joined Ferring in 2015 and has been instrumental in leading and driving change for R&D and the wider organisation, while ensuring that the business can realise its full potential in the future. In addition, Per has accelerated Ferring’s focus on the microbiome through a number of external collaborations and the recent acquisition of Rebiotix. Prior to joining Ferring, Per worked at Novo Nordisk for 12 years and served in several executive and leadership roles, including R&D and regional commercial leadership teams. Per is a qualified medical doctor and also has a PhD in Biochemistry and Clinical Chemistry.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.
# # #